| 2026 | | Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double-blind, multicentre, therapeutic confirmatory phase 3 clinical trial
Diabetes, obesity & metabolism, 28(3). : 2027-2037, 2026 | 김혜진 |
| 2025 | | Current Status of Delay in Injectable Therapy among Type 2 Diabetes Mellitus Patients in South Korea: Multicenter Retrospective Study (2015–2021)
Endocrinology and metabolism (Seoul, Korea), 40(5). : 727-736, 2025 | 김혜진 |
| 2025 | | Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes
Diabetes & metabolism journal, 49(6). : 1155-1177, 2025 | 김혜진 |
| 2025 | | Is the next STEP on the BPROAD to intensive blood pressure lowering for all type 2 diabetic patients?: consensus statements from the Korean Society of Hypertension
Clinical hypertension, 31(1). : e31-e31, 2025 | 김혜진 |
| 2025 | | Comparative Effectiveness and Safety of Moderate-Intensity Pravastatin Versus Atorvastatin in Patients with Dyslipidemia: A Retrospective Cohort Study Using a Common Data Model of Multicenter Electronic Health Records in South Korea
Journal of atherosclerosis and thrombosis, 32(10). : 1268-1303, 2025 | 김혜진 |
| 2025 | | EffiCacy and safety of ANagliptin when added to iNsulin and metformin therapy in patients with uncontrolled type 2 diAbetes; randomized, placebo-controlled, double-blind, multicentre trial (CANNA study)
Diabetes, obesity & metabolism, 27(9). : 5351-5355, 2025 | 김혜진 |
| 2025 | | 2025 clinical practice guidelines for diabetes management in korea: Recommendation of the korean diabetes association
Diabetes & metabolism journal, 49(4). : 582-783, 2025 | 김혜진 |
| 2025 | | Deferoxamine prevents dexamethasone-induced muscle atrophy by reducing MuRF1 and atrogin-1
Frontiers in pharmacology, 16. : 1582216-1582216, 2025 | 김혜진, 이관우, 이나미, 전자영, 최성이, 최재명, 한승진, 허유정 |
| 2025 | | Empagliflozin Alleviates Hepatic Steatosis and Oxidative Stress via the NRF1 Pathway in High-Fat Diet-Induced Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease
International journal of molecular sciences, 26(9). : 4054-4054, 2025 | 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
| 2024 | | 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
Diabetes & metabolism journal, 48(4). : 546-708, 2024 | 김대중, 김혜진 |
| 2024 | | Cysteine-rich 61 inhibition attenuates hepatic insulin resistance and improves lipid metabolism in high-fat diet fed mice and HepG2 cells
FASEB journal, 38(15). : e23859-e23859, 2024 | 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
| 2024 | | Effect of Pravastatin on Kidney Function in Patients with Dyslipidemia and Type 2 Diabetes Mellitus: A Multicenter Prospective Observational Study
Advances in therapy, 41(8). : 3119-3137, 2024 | 김혜진 |
| 2024 | | Imeglimin attenuates NLRP3 inflammasome activation by restoring mitochondrial functions in macrophages
Journal of pharmacological sciences, 155(2). : 35-43, 2024 | 김대중, 김혜진, 이관우, 전자영, 한승진 |
| 2024 | | A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study)
Journal of diabetes research, 2024. : 8915591-8915591, 2024 | 김혜진 |
| 2023 | | Protective effect of empagliflozin against palmitate-induced lipotoxicity through AMPK in H9c2 cells
Frontiers in pharmacology, 14. : 1228646-1228646, 2023 | 강엽, 김혜진, 이관우, 전자영, 최성이 |
| 2023 | | Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension
Diabetes & metabolism journal, 47(6). : 808-817, 2023 | 김혜진 |
| 2023 | | 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Diabetes & metabolism journal, 47(5). : 575-594, 2023 | 김대중, 김혜진 |
| 2023 | | Amphiregulin Induces iNOS and COX-2 Expression through NF- κ B and MAPK Signaling in Hepatic Inflammation
Mediators of inflammation, 2023. : 2364121-2364121, 2023 | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
| 2023 | | Impact of Post-Transplant Diabetes Mellitus on Survival and Cardiovascular Events in Kidney Transplant Recipients
Endocrinology and metabolism (Seoul, Korea), 38(1). : 139-145, 2023 | 김대중, 김혜진, 박범희, 이관우, 전자영, 한승진 |
| 2023 | | Association between Low-Density Lipoprotein Cholesterol Level and Cardiovascular Outcomes in Korean Adults: A Nationwide Cohort Study
Diabetes & metabolism journal, 47(1). : 59-71, 2023 | 김혜진 |
| 2023 | | Cardiovascular Outcomes according to Comorbidities and Low-Density Lipoprotein Cholesterol in Korean People with Type 2 Diabetes Mellitus
Diabetes & metabolism journal, 47(1). : 45-58, 2023 | 김혜진 |
| 2022 | | Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease
Biochemical and biophysical research communications, 588. : 154-160, 2022 | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
| 2022 | | Characteristics and Clinical Course of Diabetes of the Exocrine Pancreas: A Nationwide Population-Based Cohort Study
Diabetes care, 45(5). : 1141-1150, 2022 | 김대중, 김혜진, 이관우, 이나미, 전자영, 한승진 |
| 2022 | | Mitochondrial protease ClpP supplementation ameliorates diet-induced NASH in mice
Journal of hepatology, 77(3). : 735-747, 2022 | 강엽, 김혜진, 이관우, 이광, 최성이, 한승진 |
| 2022 | | Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
Diabetes & metabolism journal, 46(5). : 689-700, 2022 | 김혜진 |
| 2022 | | The Positive Association between Muscle Mass and Bone Status Is Conserved in Men with Diabetes: A Retrospective Cross-Sectional and Longitudinal Study
Journal of clinical medicine, 11(18). : 5370-5370, 2022 | 김대중, 김혜진, 정윤석, 최용준, 한승진 |
| 2022 | | Empagliflozin Reduces the Progression of Hepatic Fibrosis in a Mouse Model and Inhibits the Activation of Hepatic Stellate Cells via the Hippo Signalling Pathway
Biomedicines, 10(5). : 1032-1032, 2022 | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
| 2022 | | In Vivo Two-Photon Imaging Analysis of Dynamic Degradation of Hepatic Lipid Droplets in MS-275-Treated Mouse Liver
International journal of molecular sciences, 23(17). : 9978-9978, 2022 | 강엽, 곽종영, 김혜진, 이관우, 전자영, 최성이 |
| 2022 | | Development and psychometric evaluation of a new brief scale to measure eHealth literacy in people with type 2 diabetes
BMC nursing, 21(1). : 297-297, 2022 | 김혜진, 이관우, 이은현 |
| 2021 | | Acute glucose shift induces the activation of the nlrp3 inflammasome in thp-1 cells
International journal of molecular sciences, 22(18). : 9952-9952, 2021 | 강엽, 김대중, 김혜진, 이관우, 한승진 |
| 2021 | | Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF- κ B, MKK7/JNK, and JAK2/STAT1 Signalling Pathways
Journal of immunology research, 2021. : 9944880-9944880, 2021 | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
| 2021 | | Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model
Journal of gastroenterology and hepatology, 36(9). : 2592-2600, 2021 | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
| 2021 | | Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
Frontiers in pharmacology, 12. : 689885-689885, 2021 | 김혜진 |
| 2021 | | Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study
Diabetes therapy, 12(11). : 2907-2920, 2021 | 김혜진, 이관우 |
| 2020 | | A Class I Histone Deacetylase Inhibitor Attenuates Insulin Resistance and Inflammation in Palmitate-Treated C2C12 Myotubes and Muscle of HF/HFr Diet Mice
Frontiers in pharmacology, 11. : 601448-601448, 2020 | 강엽, 김혜진, 이관우, 전자영, 최성이 |
| 2020 | | Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study
Cardiovascular diabetology, 19(1). : 95-95, 2020 | 김혜진 |
| 2020 | | Hypoglycemia and Dementia Risk in Older Patients with Type 2 Diabetes Mellitus: A Propensity-Score Matched Analysis of a Population-Based Cohort Study
Diabetes & metabolism journal, 44(1). : 125-133, 2020 | 김대중, 김혜진, 문소영, 이관우, 전자영, 한승진 |
| 2020 | | Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial
Clinical therapeutics, 42(10). : 2021-2035.e1-e3, 2020 | 김혜진 |
| 2020 | | CCL20 induced by visfatin in macrophages via the NF-kappaB and MKK3/6-p38 signaling pathways contributes to hepatic stellate cell activation
Molecular biology reports, 47(6). : 4285-4293, 2020 | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진 |
| 2020 | | Body Fat Is Related to Sedentary Behavior and Light Physical Activity but Not to Moderate-Vigorous Physical Activity in Type 2 Diabetes Mellitus
Diabetes & metabolism journal, 44(2). : 316-325, 2020 | 김혜진 |
| 2019 | | Visfatin Induces Inflammation and Insulin Resistance via the NF-kappaB and STAT3 Signaling Pathways in Hepatocytes
Journal of diabetes research, 2019. : 4021623-4021623, 2019 | 강엽, 김대중, 김혜진, 이관우, 전자영, 최성이, 한승진 |
| 2019 | | Sodium fluorocitrate having inhibitory effect on fatty acid uptake ameliorates high fat diet-induced non-alcoholic fatty liver disease in C57BL/6J mice
Scientific reports, 9(1). : 17839-17839, 2019 | 강엽, 김혜진, 이관우, 이수진, 최성이, 한승진 |
| 2019 | | 2018 Guidelines for the management of dyslipidemia in Korea
The Korean journal of internal medicine, 34(5). : 1171-1171, 2019 | 김혜진 |
| 2019 | | 2018 Guidelines for the management of dyslipidemia
The Korean journal of internal medicine, 34(4). : 723-771, 2019 | 김혜진 |
| 2019 | | GLP1 improves palmitateinduced insulin resistance in human skeletal muscle via SIRT1 activity
International journal of molecular medicine, 44(3). : 1161-1171, 2019 | 강엽, 김대중, 김혜진, 이관우, 전자영, 최성이, 한승진 |
| 2019 | | The association of diabetes duration and glycemic control with depression in elderly men with type 2 diabetes mellitus
Journal of research in medical sciences, 24. : 17-17, 2019 | 김대중, 김혜진, 이관우, 한승진, 홍창형 |
| 2019 | | Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report
Diabetes therapy, 10(4). : 1271-1282, 2019 | 김혜진, 이관우 |
| 2019 | | The Association of Adiponectin and Visceral Fat with Insulin Resistance and beta-Cell Dysfunction
Journal of Korean medical science, 34(1). : e7-e7, 2019 | 김대중, 김혜진, 문현욱, 하경화, 한승진 |
| 2019 | | Correction: Kim, Young-Gun: Jeon, Ja Young: Kim, Hae Jin: Kim, Dae Jung: Lee, Kwan-Woo: Moon, So Young: Han, Seung Jin. Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors versus Sulfonylureas: A Real-World Population-Based Cohort Study. Journal of Clinical Medicine 2019, 8, 28
Journal of clinical medicine, 8(3). : 389-389, 2019 | 김대중, 김혜진, 문소영, 이관우, 전자영, 한승진 |
| 2019 | | Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study
Journal of clinical medicine, 8(1). : 28-28, 2019 | 김대중, 김혜진, 문소영, 이관우, 전자영, 한승진 |
